287 filings
Page 3 of 15
6-K
287w7m6n5w r7
26 Sep 11
YM BioSciences Announces Nimotuzumab Data to be Reported at 2011 ECCO-ESMO Conference
12:00am
6-K
nydh sbihofe0x
23 Sep 11
YM BioSciences Reports Fiscal 2011 Year End Operational and Financial Results
12:00am
6-K
60xmgtn
23 Sep 11
Current report (foreign)
12:00am
6-K
i865l8r3tu8jlm
4 Aug 11
Current report (foreign)
12:00am
6-K
5auao6l
7 Jul 11
Current report (foreign)
12:00am
6-K/A
a1ks6yz8sygp48vhya5q
3 Jun 11
Current report (foreign) (amended)
12:00am
6-K
9ji hc24ys4kl9z
3 Jun 11
YM BioSciences Reports Interim Phase I/II Data for its JAK1/JAK2 Inhibitor CYT387 at ASCO
12:00am
6-K
k2y7wyyymjw 68
31 May 11
YM BioSciences Provides Update on the Development Program for Nimotuzumab
12:00am
6-K
gi9ujpvpjl6
31 May 11
Current report (foreign)
12:00am
6-K
wocy8 ivg1g
19 May 11
YM BioSciences Reports Updated 12-Week Phase I/II Results for its JAK1/JAK2 Inhibitor CYT387
12:00am
6-K
ro71v1 sc6
12 May 11
YM BioSciences Reports Fiscal Third Quarter 2011
12:00am
6-K
klmflxtk
12 May 11
Current report (foreign)
12:00am
6-K
asgwc6
18 Apr 11
YM BioSciences Reports Positive Updated Anemia Response Data
12:00am
6-K
p5ftrac89r8sx
18 Mar 11
Current report (foreign)
12:00am
6-K/A
hhkf742t uqqk
18 Mar 11
Current report (foreign) (amended)
12:00am
6-K
mwq0ygoj3 a8
11 Feb 11
Current report (foreign)
12:00am
6-K
z0mv1rnkjpwvhacx0ek
10 Feb 11
YM BioSciences Reports Fiscal Second Quarter 2011 Operational
12:00am
6-K
h3mx6nv9j 2blsxi6ffr
21 Jan 11
YM BioSciences Announces Data from Nimotuzumab Phase II Gastric Cancer Trial Reported at ASCO GI Symposium
12:00am
6-K
a3k1irqox4oak2v4ke
12 Jan 11
Amendment No. 1 to the Sales Agreement
12:00am
6-K
pbuw7f4g hrb9e0
6 Jan 11
Current report (foreign)
12:00am